EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC

ABSTRACT Hypoxia occurs frequently in human cancers and promotes stabilization and activation of hypoxia inducible factor (HIF). HIF-1α is specific for the hypoxia response, and its degradation mediated by three enzymes EGLN1, EGLN2 and EGLN3. Although EGLNs expression has been found to be related to prognosis of many cancers, few studies examined DNA methylation in EGLNs and its relationship to prognosis of early-stage non-small cell lung cancer (NSCLC). We analyzed EGLNs DNA methylation data from tumor tissue samples of 1,230 early-stage NSCLC patients, as well as gene expression data from The Cancer Genome Atlas. The sliding windows sequential forward feature selection method and weighted random forest were used to screen out the candidate CpG probes in lung adenocarcinomas (LUAD) and lung squamous cell carcinomas patients, respectively, in both discovery and validation phases. Then Cox regression was performed to evaluate the association between DNA methylation and overall survival. Among the 34 CpG probes in EGLNs, DNA methylation at cg25923056EGLN2 was identified to be significantly associated with LUAD survival (HR = 1.02, 95% CI: 1.01–1.03, P = 9.90 × 10–5), and correlated with EGLN2 expression (r = – 0.36, P = 1.52 × 10–11). Meanwhile, EGLN2 expression was negatively correlated with HIF1A expression in tumor tissues (r = – 0.30, P = 4.78 × 10–8) and significantly (P = 0.037) interacted with HIF1A expression on overall survival. Therefore, DNA methylation of EGLN2- HIF1A is a potential marker for LUAD prognosis and these genes are potential treatment targets for further development of HIF-1α inhibitors in lung cancer therapy.

[1]  M. Esteller,et al.  A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer , 2018, Molecular oncology.

[2]  Xihong Lin,et al.  Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC , 2018, Clinical Epigenetics.

[3]  Cleo C. van Diemen,et al.  COPD GWAS variant at 19q13.2 in relation with DNA methylation and gene expression , 2017, Human molecular genetics.

[4]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[5]  Yang Zhao,et al.  Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma , 2017, Clinical Epigenetics.

[6]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[7]  Y. Shah,et al.  Hypoxia-inducible factors: a central link between inflammation and cancer. , 2016, The Journal of clinical investigation.

[8]  Tom R. Gaunt,et al.  Systematic identification of genetic influences on methylation across the human life course , 2016, Genome Biology.

[9]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Vessela Kristensen,et al.  Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis , 2015, Molecular oncology.

[11]  Jan Budczies,et al.  Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes , 2016, International journal of cancer.

[12]  R. Govindan,et al.  Genomic alterations in lung adenocarcinoma. , 2015, The Lancet. Oncology.

[13]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[14]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[15]  D. Schübeler.  Function and information content of DNA methylation , 2015, Nature.

[16]  T. Therneau,et al.  An Introduction to Recursive Partitioning Using the RPART Routines , 2015 .

[17]  Yi Wang,et al.  Genome-wide Association Study of Survival in Early-stage Non-Small Cell Lung Cancer , 2015, Annals of Surgical Oncology.

[18]  Johan Staaf,et al.  Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.

[19]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[20]  Hai-bo Xiao,et al.  Over-expression of prolyl hydroxylase-1 blocks NF-κB-mediated cyclin D1 expression and proliferation in lung carcinoma cells. , 2014, Cancer genetics.

[21]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Jagodziński,et al.  Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer , 2013, BMC Cancer.

[23]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[24]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[25]  Houjie Liang,et al.  Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer , 2012, Experimental biology and medicine.

[26]  A. Jukkola-Vuorinen,et al.  Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients , 2012, Breast Cancer Research and Treatment.

[27]  Sabine U. Vorrink,et al.  Aberrant Promoter CpG Methylation Is a Mechanism for Impaired PHD3 Expression in a Diverse Set of Malignant Cells , 2011, PloS one.

[28]  E. Feierstein,et al.  DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing , 2011, PloS one.

[29]  J. Rinn,et al.  DNA methylation and epigenetic control of cellular differentiation , 2010, Cell cycle.

[30]  S. Fox,et al.  DNA methylation analysis of the HIF‐1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas , 2010, Histopathology.

[31]  D. Lobo,et al.  Expression of key hypoxia sensing prolyl‐hydroxylases PHD1, ‐2 and ‐3 in pancreaticobiliary cancer , 2010, Histopathology.

[32]  J. Meyerhardt,et al.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. , 2010, The American journal of pathology.

[33]  M. Simon,et al.  Hypoxia-inducible factors in stem cells and cancer , 2009, Journal of cellular and molecular medicine.

[34]  Rui Jiang,et al.  A random forest approach to the detection of epistatic interactions in case-control studies , 2009, BMC Bioinformatics.

[35]  P. Bedossa,et al.  Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors , 2008, Clinical Cancer Research.

[36]  David C Christiani,et al.  Second hand smoke, age of exposure and lung cancer risk. , 2007, Lung cancer.

[37]  Adrian Bird,et al.  Perceptions of epigenetics , 2007, Nature.

[38]  Brian Keith,et al.  Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.

[39]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[40]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[41]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[42]  Varda Rotter,et al.  Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. , 2003, Cancer research.

[43]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[44]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[45]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[46]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[47]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.